Ginkgo Bioworks Holdings Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.41 (market cap $763.64M), while ZIM Integrated Shipping Services Ltd trades at $30.16 (market cap $3.65B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 4.8× Ginkgo Bioworks Holdings Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| DNA | ZIM | |
|---|---|---|
Market Cap | $763.64M | $3.65B |
Volume | 3,204,177 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $15.83 | $30.51 |
52-Week Low | $5.48 | $12.44 |
Typical Hold Time | 7 Days | 27 Days |
Enterprise Value | $865.59M | $7.32B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
ZIM Integrated Shipping Services trades at $30.31, up 1.07% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $6.9B in 2025 to $6.4B in 2026 and net income dropping from $479M to $139M, though Q2 2026 earnings beat expectations. Recent news highlights a potential $35 per share acquisition offer from Hapag-Lloyd pending Israeli government approval, creating significant uncertainty.
The investment outlook balances acquisition upside against operational challenges. While valuation metrics appear reasonable (P/E 26.31, P/S 0.57), declining profitability and the uncertain merger outcome present substantial risk. Analyst sentiment remains cautious with no buy ratings, reflecting concerns about the company's standalone prospects if the acquisition fails to materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →